Advanced Search

Home > Journals > Minerva Pediatrica > Past Issues > Minerva Pediatrica 2016 December;68(6) > Minerva Pediatrica 2016 December;68(6):478-86

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUEMINERVA PEDIATRICA

A Journal on Pediatrics, Neonatology, Adolescent Medicine,
Child and Adolescent Psychiatry

Indexed/Abstracted in: CAB, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,532

Frequency: Bi-Monthly

ISSN 0026-4946

Online ISSN 1827-1715

 

Minerva Pediatrica 2016 December;68(6):478-86

    REVIEWS

Usefulness of fecal calprotectin determination in pediatric intestinal diseases

Chiara ROSSO 1, Gian P. CAVIGLIA 1, Rinaldo PELLICANO 2

1 Department of Medical Sciences, University of Turin, Turin, Italy; 2 Unit of Gastroenterology, Città della Salute e della Scienza-Molinette Hospital, Turin, Italy

Calprotectin is a heterodimeric protein which belongs to the calcium-binding protein S100 family. Calprotectin is released by leukocytes at the site of inflammation and it can be detected in the feces where it remains stable for about a week. Hence, increased fecal calprotectin (FC) levels are found in several inflammatory conditions, mainly the inflammatory bowel diseases (IBD). In the setting of pediatric gastroenterology, the importance of FC has increased over time. This review aims to summarize the most recent findings concerning the role of FC in the algorithm of different inflammatory and non-inflammatory conditions among pediatric patients. Increasing evidences support the use of this biomarker for diagnosis, follow-up and evaluation of response to therapy of several pediatric gastrointestinal diseases, ranging from IBD to lymphocytic/ eosinophilic/ and nonspecific colitis and necrotizing enterocolitis. More efforts should be done to clarify the optimal cut-off of FC levels in patients younger than 5 years.

language: English


FULL TEXT  REPRINTS

top of page